Cargando…

Challenges of driving CD30-directed CAR-T cells to the clinic

Chimeric antigen receptor T (CAR-T) cells are a promising new treatment for patients with relapsed or refractory hematologic malignancies, including lymphoma. Given the success of CAR-T cells directed against CD19, new targets are being developed and tested, since not all lymphomas express CD19. CD3...

Descripción completa

Detalles Bibliográficos
Autores principales: Grover, Natalie S., Savoldo, Barbara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6404322/
https://www.ncbi.nlm.nih.gov/pubmed/30841880
http://dx.doi.org/10.1186/s12885-019-5415-9